FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT	OF CHANG	GES IN BE	NEFICIAL

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

														_						
1. Name and Address of Reporting Person*					<u>A\</u>	2. Issuer Name and Ticker or Trading Symbol AVADEL PHARMACEUTICALS PLC AVDL]									5. Relationship of Report (Check all applicable) Director			10% Owner		
(Last)	(Fi	First) (Middle)			<u> </u>	Date of Earliest Transaction (Month/Day/Year)								_ >	Officer below)	er (give title v) See Remai		Other (s below)	specify	
BLOCK 10-1, BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN						01/03/2017									occ remarks					
(Street)						4. If Amendment, Date of Original Filed (Month/Day/Year) $01/03/2017$								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
DUBLIN	UBLIN L2 15														Form filed by More than One Reporting Person					
(City)	(S	•	(Zip)																	
1 Title of	Socurity (Inc		le I - Nor	1-Deriv			2A. Deemed		uired,	Dis	posed of				y Owned		6 Ow	nership	7. Nature	
1. Title of Security (Instr. 3)			Date	Date Execution Date, (Month/Day/Year) if any		Execution Date,		Transaction Code (Instr.						Securitie Beneficia	es For ally (D) Following (I) (: Direct Indirect str. 4)	of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amount	(A) or (D)		Price	Transact	nsaction(s) str. 3 and 4)			(11301.4)				
ADSs ⁽¹⁾			01/03	3/2017				A ⁽²⁾	A ⁽²⁾ 33,000 ⁽²⁾		3)	A	\$0(4) 33		,000		D			
		٦									osed of, o				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	cution Date,		iction Instr.	Derivative		6. Date Exercisa Expiration Date (Month/Day/Yea		te Amount of		tr. 3	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				,	Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amo or Num of Si	ber		Transaction(s) (Instr. 4)				
Stock Option (right to buy)	\$21.67	01/03/2017			A ⁽²⁾		100,000		(5)		06/26/2025	ADS	100	,000	\$0 ⁽⁴⁾	100,000	0	D		
Stock Option (right to buy)	\$14.35	01/03/2017			A ⁽²⁾		50,000		(6)		12/10/2025	ADS	50,	000	\$0 ⁽⁴⁾	50,000		D		
Stock Option (right to buy)	\$10.4	01/03/2017			A ⁽²⁾		80,000		(7)		12/14/2026	ADS	80,	000	\$0 ⁽⁴⁾	80,000		D		

Explanation of Responses:

- 1. The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value \$0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
- 2. On 12/31/16, Flamel Technologies S.A. ("Flamel") merged with and into Avadel Pharmaceuticals plc ("Avadel"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person filed a Form 4 solely to report dispositions of Flamel securities as a result of the Merger, and filed a Form 3 to reflect the reporting person's new status as a director and/or executive officer of Avadel. This Form 4 reports the reporting person's acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in the Form 4 referenced above or the acquisitions reported in this Form 4.
- 3. Includes (a) 20,000 restricted ADSs granted under the issuer's "Free Share" award program on 8/10/2016, all of which will be issued to the reporting person on the second anniversary of the grant date; and (b) 10,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date.
- 4. Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively.
- 5. Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 06/26/2015 grant date.
- 6. Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 12/10/2015 grant date. Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 12/10/2015 grant date.
- 7. Options become exercisable as to 20,000 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.

Remarks:

Sr. VP, Quality and Reg. Affairs. This amendment to the Form 4 filed by the reporting person on January 3, 2017 (the "Original Form 4") is being filed to correct the nominal value of the issuer's ordinary shares as described in footnote #1 to the Original Form 4.

> /s/ Phillandas T. Thompson, as 01/13/2017 attorney-in-fact for Sandra L. Hatten

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.